BioCentury
ARTICLE | Targets & Mechanisms

HCV cache: the list

January 7, 2010 8:00 AM UTC

Researchers at The Scripps Research Institute have used a cell-based model of HCV infection to identify compounds on the market or in development for other indications that could be repurposed to treat HCV.1 But if repurposing the molecules is not feasible, the scaffolds of those compounds could serve as the basis of new HCV therapies.

Standard therapy for HCV infection includes a 48-week course of pegylated interferon-a (PEG-INF-a) and ribavirin for HCV genotype 1 or a 24-week course of the two drugs for genotypes 2 and 3. The regimen only works in 50%-60% of patients and causes a host of side effects...